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Introduction: The Xpert MTB/RIF test detects DNA from Mycobacterium tuberculosis complex 
and susceptibility to rifampin. It has been evaluated repeatedly under “ideal” conditions including 
centrifugation of sputum and bronchoalveolar lavage, Ziehl Neelsen (ZN) and auramine/rhodamine 
staining, as well as with solid and liquid automated culture methods. Results from such evaluations 
cannot be extrapolated to low-income countries that do not routinely use all these processes.
Objective: To assess the performance of the Xpert MTB/RIF test in respiratory samples under “real” 
conditions of work in a low-income country and its correlation with phenotypic susceptibility testing.
Materials and methods: We conducted a cross-sectional study to assess the performance of the 
Xpert MTB/RIF test in ≥12 year-old patients with suspected pulmonary tuberculosis. In routine sample 
processing at the Hospital we do not use sputum centrifugation, staining with auramine/rhodamine or 
automated liquid culture. 
Results: We screened 152 patients of whom 108 were eligible for the study and 103 were included in 
the analysis; 34% of the samples were positive. The overall test sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) were 91%, 92%, 83% and 96%, respectively. In ZN-
negative samples the sensitivity, specificity, PPV and NPV were 87%, 91%, 68% and 97%, respectively. 
The results of sensitivity and resistance to rifampin were concordant with susceptibility testing using the 
multiple proportions method (kappa=1, p<0.0001).
Conclusions: The Xpert MTB/RIF test overall performance was similar to the one achieved under 
ideal conditions. Its performance in ZN-negative samples was better under “real” conditions of work in 
a low-income country.
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Rendimiento de la prueba Xpert MTB/RIF en muestras respiratorias en el escenario real de 
trabajo en un país en desarrollo
Introducción. La prueba Xpert MTB/RIF detecta el ADN del complejo Mycobacterium tuberculosis 
y la sensibilidad a rifampicina. La prueba ha sido evaluada en condiciones “ideales” que incluyen la 
centrifugación de esputo y el lavado broncoalveolar, la tinción de Ziehl Neelsen (ZN) y de auramina-
rodamina y los métodos de cultivo sólido y de cultivo líquido automatizado. Los resultados de tales 
evaluaciones no pueden extrapolarse a países de bajos ingresos que no utilizan habitualmente todos 
estos procesos.
Objetivo. Evaluar el rendimiento de la prueba Xpert MTB/RIF en muestras respiratorias bajo condiciones 
“reales” de trabajo y su correlación con las pruebas fenotípicas de sensibilidad.
Materiales y métodos. Se llevó a cabo un estudio transversal para evaluar el rendimiento de la prueba 
Xpert MTB/RIF en pacientes ≥12 años con sospecha de tuberculosis pulmonar. En el procesamiento 
rutinario de muestras en el Hospital del estudio no se usa la centrifugación del esputo, la tinción con 
auramina-rodamina ni el cultivo líquido automatizado.
Resultados. Se incluyeron 152 pacientes, de los cuales 108 eran elegibles y 103 se incluyeron en 
el análisis. El 34 % de las muestras fueron positivas; la sensibilidad de la prueba fue de 91 %, la 
especificidad de 92 %, el valor diagnóstico positivo de 83 % y el valor diagnóstico negativo global 
de 96 %. En las muestras negativas con Ziehl Neelsen, la sensibilidad fue de 87 %, la especificidad 
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de 91 % y los valores diagnósticos positivo y negativo alcanzaron 68 y 97 %, respectivamente. Los 
resultados de sensibilidad o resistencia a la rifampicina concordaron con los de la prueba fenotípica 
de sensibilidad (valor de kappa=1, p<0,0001).
Conclusiones. El rendimiento global de la prueba fue similar al obtenido bajo condiciones “ideales”. 
En las muestras negativas con Ziehl Neelsen se obtuvo un mejor rendimiento en las condiciones 
“reales” de trabajo de un país de bajos ingresos. 
Palabras clave: Mycobacterium tuberculosis, tuberculosis, reacción en cadena de la polimerasa, 
rifampicina. 
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Among infectious diseases, tuberculosis is a major 
cause of morbidity and mortality in the world and 
it is considered a public health problem mainly in 
developing countries. In 2011, 8.7 million people 
contracted the disease and 1.4 million died (1).
Historically, bacilloscopy and culture of respiratory 
samples have been used for the diagnosis of 
pulmonary tuberculosis. Bacilloscopy has a low 
diagnostic performance (sensitivity, 40-60%), and 
although culture is more sensitive, 4 to 8 weeks 
are required for bacilli isolation in solid media, and 
2 to 4 weeks in automated liquid cultures, which is 
enough time for the propagation of sensitive and 
multidrug resistant (MDR) bacteria, posing signi-
ficant challenges for the control of the disease (2-5).
Polymerase chain reaction (PCR) has revolu-
tionized microbiology by facilitating direct detection 
and identification of infectious agents in clinical 
specimens in a short time (4). The recently 
introduced Xpert MTB/RIF® test (Cepheid, Inc., 
Sunnyvale, California, USA) detects the presence 
of Mycobacterium tuberculosis DNA, as well 
as susceptibility to rifampin (RIF) in real time 
by recognizing rpoB gene mutations in a single 
reaction. Monoresistance to rifampin is rare, and 
it is estimated that over 90% of rifampin-resistant 
strains also exhibit some degree of resistance to 
isoniazid (INH); thus, detecting RIF resistance can 
be useful as an MDR tuberculosis marker. This 
molecular test can reduce to two hours the time it 
takes to have results from conventional phenotypic 
sensitivity tests to antimicrobial agents (method of 
multiple proportions) (5-7).
The Xpert MTB/RIF® test has been evaluated 
repeatedly under ideal conditions including spu-
tum and bronchoalveolar lavage processed with 
centrifugation, ZN and auramine/rhodamine stain-
ing, as well as solid culture and liquid automated 
culture. The results of such evaluations cannot be 
extrapolated to many low-income countries that do 
not use these processes routinely (6,8).
The aim of this study was to assess the performance 
of the Xpert MTB/RIF® test for the diagnosis of 
pulmonary tuberculosis in respiratory samples 
compared with culture and its correlation with 
phenotypic susceptibility testing in “real” working 
conditions in a developing country hospital with high 
prevalence of the disease and limited resources (9). 
The study was conducted in the city of Medellín, 
Colombia, where tuberculosis incidence amounts 
to 78.9 cases per 100,000 population as reported 
by the bulletin of the Dirección Seccional de 
Antioquia, 2012.
Materials and methods
Study settings
A cross-sectional study was conducted in order 
to evaluate the Xpert MTB/RIF diagnostic test 
accuracy in identifying pulmonary tuberculosis 
disease in patients from the Hospital Universitario 
San Vicente Fundación in Medellín, Colombia, from 
September 2010 to December 2011. The Hospital 
Ethics Committee approved the study.
Study participants
Participants were chosen from among ≥12 year-
old patients with clinical suspicion of pulmonary 
tuberculosis. Clinical suspicion of tuberculosis was 
defined in HIV-negative patients as cough for 14 or 
more days and in HIV-positive patients as cough 
during any period of time, while as well as in other 
patients with concurrent abnormal chest x-ray 
(cavity, focal opacity, pleural effusion or nodule).
Sample collection and processing 
The respiratory samples analyzed were sputum, 
bronchoalveolar lavage or tracheal aspirate (one 
sample per patient). All samples were stained with 
Ziehl-Neelsen (ZN), inoculated in Ogawa-Kudoh 
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(OK) culture and tested with the Xpert MTB/
RIF® assay. Samples were processed following 
the hospital protocol and the test manufacturer’s 
recommendations.
Bronchoalveolar lavage was centrifuged at 3,500 
gravities for 30 minutes in refrigerated centrifuge 
(Hettich®), and the supernatant was discarded 
leaving 2 ml of sediment; 1 ml was taken for 
standard tests (ZN stain and OK culture) and 1 ml 
for molecular testing. Sputum and tracheal aspirate 
did not undergo centrifugation.
Microbiological culture samples were decontamina-
ted with sodium hydroxide (NaOH) 4% and cultured 
using the Kudoh swab method (direct method) in two 
tubes with Ogawa-Kudoh medium; liquid medium 
was not used. The culture was incubated at 37°C 
in horizontal position for 8 weeks and reading was 
performed each week; after the eighth week, if no 
growth was seen, it was reported as negative.
Molecular Xpert MTB/RIF® test. The cartridge 
contains a sample processing control (lyophilized 
Bacillus globigii) to ensure the proper processing 
of target bacteria and to monitor the presence of 
inhibitors, and five probes with a wild phenotype 
of M. tuberculosis. The sodium hydroxide- and 
isopropanol-containing reagent was added to the 
sample in a 2:1 (v/v) ratio. This mixture was stirred 
by vortex for 5 seconds and subsequently incubated 
at room temperature for 15 minutes until the sample 
was completely homogeneous. Then, 2 ml were 
transferred to the Xpert MTB/RIF® cartridge, which 
was then loaded into the GeneXpert® instrument 
where DNA extraction, real-time PCR and detection 
processes are fully automated. Each clinical sample 
was tested once regardless of the outcome.
The implementation protocol and results analysis 
were done using the GeneXpertDx System software 
version 4.3. The detection of the five specific 
probes for M. tuberculosis complex rpoB gene was 
considered a positive result. Trials in which the M. 
tuberculosis signal was negative but positive for 
the extraction and amplification internal control 
were considered as a negative result. Rifampin 
resistance was determined by failed or delayed 
hybridization of at least one or more rpoB gene 
specific probes.
Conventional susceptibility testing. The multiple 
proportions method is the test used to detect 
sensitivity of frontline anti-TB drugs (isoniazid, 
rifampin, ethambutol and streptomycin). Respiratory 
samples were sent to the Laboratorio de Salud 
Pública de Antioquia, where the test has been 
standardized according to the process described 
by Canetti and Grosset (10).
Statistical analysis
Microsoft Excel® 2010 was used for the database 
and to calculate the frequencies and the measures of 
central tendency. Epidat 3.1 software (Panamerican 
Health Organization) was used for calculations of 
validity: sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), like-
lihood ratio and kappa coefficient. Test sensitivity, 
specificity and predictive values were calculated 
with reference to the culture in solid medium.
Results
From September, 2010, to December, 2011, 152 
patients were screened, out of which 108 were 
eligible for the study and 103 were included in the 
analysis, as shown in figure 1. The bronchoalveolar 
lavage represented 61% (63) of the samples, 
sputum, 35% (36) and tracheal aspirate, 4% (4). 
Seropositivity for the human immunodeficiency 
Figure 1. Study algorithm
152 patients screened 
108 eligible patients
22 patients under 12 years old
12 outpatients
10 with no clinical suspicion criteria 
Ogawa-Kudoh culture
Xpert MTB / RIF
Löwenstein-Jensen culture,
multiple proportions method
Ziehl Neelsen stain
Repiratory sample
If positive
5 samples contaminated
(reference standard test)
103 patients included
in the analysis
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virus (HIV) was found in 19.4% of the patients, with 
a median CD4 of 40xuL; no history of tuberculosis 
or antiretroviral therapy was found (ART) (table 1).
The Xpert MTB/RIF® test was positive in 35 of the 
103 samples. In 5.6% (6) of the cases the test was 
positive with negative culture while 2.9% (3) were 
culture-positive PCR-negative cases (table 2).
The overall sensitivity of the Xpert MTB/RIF® test 
was 91%, specificity, 92%, PPV, 83% and NPV, 
96%. Its performance in samples with positive and 
negative ZN staining is shown in table 3. Of the 
35 positive samples, 91.4% (31) were sensitive 
to RIF and 8.6% (3) were resistant. The results 
regarding sensitivity and resistance to rifampin were 
concordant with susceptibility testing using the 
multiple proportions method (Kappa = 1 p <0.0001).
Discussion
The Xpert MTB/RIF® test is a useful tool for early 
diagnosis and treatment of pulmonary tuberculosis. 
Having the results regarding rifampin resistance in 
two hours allows choosing the therapy appropriately, 
and thus reducing the probability of resistance to 
other drugs during treatment, as well as decreasing 
the time of patient infectivity and the appearance 
of aftermath. Its relevance as a diagnostic tool is 
foremost when respiratory samples are ZN-negative 
because it reduces the time to start treatment and it 
is not necessary to wait for culture results (10-12). 
The Xpert MTB/RIF® test has high specificity to 
detect only M. tuberculosis DNA. It has been 
evaluated in 89 non-tuberculosis bacteria, fungi 
and viruses with no false positives (13). The last 
steps of the assay (polymerase chain reaction) are 
highly susceptible to samples contamination, but 
as these are kept in a sealed container, there is 
no possibility of contamination and, therefore, of 
having false positives.
The interpretation of test results in a clinical patient 
context is very important. The Xpert MTB/RIF® 
test cannot differentiate between live and dead M. 
tuberculosis bacilli (e.g., patients in treatment or 
previously treated). Given that there is no perfect 
gold standard, the decision whether to treat or not 
a patient when the test is positive and the culture is 
negative depends on the clinical pre-test probability. 
In a study of 105 patients with culture-negative 
samples that had been treated for tuberculosis on 
the basis of clinical symptoms, 29.3% had positive 
results on the Xpert MTB/RIF test (6).
There are some limitations in most hospitals “real” 
work scenarios in developing countries, as they do 
not meet the ideal conditions established by the 
most important test-validation studies.
Hospital Universitario San Vicente sees a large 
number of patients; there is, therefore, a significant 
amount of clinical samples to process in the labo-
ratory, but limited availability of additional staff for 
reading the smears. These conditions may result in 
having to reduce the recommended time for reading 
Table 1. General characteristics
Total number of 
patients (N=103)
Median age (IQR)
Gender: Male/Female (%)
HIV- / HIV+ (%)
Respiratory samples: BAL/Sputum/TA
HIV
CD4 x µl (IQR)
ART Yes/No
History of tuberculosis
Caverns in Rx or CT scan
No HIV:
History of tuberculosis
Caverns in Rx or CT scan
Transplant
37.5 (27-49)
45 (43.6%) - 58 (56.4%)
83 (80.6%) / 20 (19.4%)
63/36/4
20
40 (20.5 -55)
0/20
0
0
83
8
10
8
Rx: radiography, CT: computed tomography, BAL: bronchoalveolar lavage, 
TA: tracheal aspirate, IQR: interquartile range, ART: antiretroviral therapy, 
HIV: human immunodeficiency virus
Table 2. Interpretation of ZN, Xpert MTB/RIF® and cultures results in the study population
Number
of patients (%)
Reference result
(Ogawa-Kudoh)
Xpert MTB/
RIF®
Ziehl Neelsen 
Respiratory samples
Interpretation
16 (15.5)
13 (12.6)
  2 (1.94)
64 (62.2)
  0
  1 (0.97)
  6 (5.82)
  1 (0.97)
+
+
+
-
-
-
-
+
+
+
-
-
+
-
+
-
+
-
-
-
+
+
-
+
Full agreement
False negative Ziehl Neelsen
False negative Xpert/Ziehl Neelsen
Full agreement
False positive Xpert/Ziehl Neelsen
False positive Ziehl Neelsen
False positive Xpert
False negative Xpert
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each sputum sample (15 minutes) (14). In our case, 
we did not perform routine sputum centrifugation, 
which reduces the sensitivity of the method by 18% 
(15); additionally, we had no availability of fluores-
cence microscopy for processing samples with 
auramine/rhodamine staining. These conditions may 
have resulted in some samples classified as ZN-
negative samples that could have been actually 
positive, the explanation being an increased sen-
sitivity of the Xpert test in our ZN-negative samples 
compared with more controlled multicenter studies, 
since its performance is directly proportional to the 
bacterial load in the sample (6,7). 
Another aspect to be considered is the culture media 
used. In most of the research studies published two 
culture media were used to assess the performance 
of the Xpert MTB/RIF® test: the Löwenstein-Jensen 
solid medium and the BACTEC MGIT automated 
liquid medium; however, many hospitals only have 
the Ogawa-Kudoh solid medium. It is known that 
the use of solid and liquid culture media can increase 
the sensitivity by 11% or more (16,17). The conven-
tional culture medium requires 102 mycobacteria to 
detect positivity and the PCR requires only 10 or 
more mycobacteria. It may have happened that as 
only solid medium was used, Xpert MTB/RIF® test 
results in some samples were positive with negative 
culture and this could have been wrongly interpreted 
as false positives. There is little information in the 
literature on the clinical outcome of these patients 
over time (as regards developing the disease or 
not) (18). In this study we did not conduct clinical or 
microbiological monitoring over time. We used the 
Ogawa-Kudoh medium to evaluate the performance 
of the Xpert MTB/RIF® test which, to our knowledge, 
had not been done previously. The Ogawa-Kudoh 
medium has shown to have the same performance 
as the Löwenstein-Jensen medium for the diagnosis 
of M. tuberculosis infection (19).
Considering the above, in ZN-negative samples 
from our population the sensitivity was higher than 
that reported in studies conducted under “ideal” 
conditions. Performance in ZN-positive samples 
is similar to that in previous reports (6,7). A 
sensitivity of 87% and a specificity of 91%, with 
an NPV of 97% in ZN-negative samples, makes 
the test a very useful tool to rule out the disease 
in the conditions described.
Larger studies (including pharmacoeconomic stud-
ies) are required to assess the true impact of the 
massive implementation of this test as a diagnostic 
method in our population, as it has the great 
advantage of requiring little preparation and han-
dling of the samples; it allows the processing of 
multiple samples in time, and it is a fully automated 
method. Its cost (approximately USD$250 per test 
in Colombia), however, is a disadvantage.
It should be noted that we included few HIV-positive 
cases and this may be a limitation to extrapolate 
the data to this group of patients. However, it 
seems that the diagnostic yield in this population 
may be better (20).
We found a high correlation between the gold stan-
dard method (proportion method) and molecular 
testing to detect sensitivity/resistance to RIF, similarly 
to that described by other studies, thus confirming 
that it is a reliable and reproducible test (6,7,16,20); 
this allows to detect early resistance and to initiate a 
prompt treatment preventing the spread or selection 
of resistant strains due to inadequate treatment. The 
national surveillance study on resistance to anti-TB 
drugs conducted in Colombia during 2004 and 2005 
showed a prevalence of MDR-TB among untreated 
patients of 2.38% (95% CI 1.58 - 3.57) and of 50.6% 
among patients classified in Category I treatment 
failure (basic scheme for new tuberculosis patients) 
(21). In a recent study, a molecular test reduced MDR-
TB detection time from 67.3 days (solid medium) and 
21.6 days (liquid medium) to less than 5 days (4.2 
days) compared to phenotypic methods (22).
In conclusion, the Xpert MTB/RIF® test is an addi-
tional tool for diagnosing pulmonary tuberculosis 
in developing countries which shows a better per-
formance in ZN-negative samples than what was 
previously reported in the literature. As has been 
reported, the outcome of RIF-resistance or sensitivity 
detection through the identification of mutations in the 
rpoB gene is consistent with the phenotypic testing, 
which means the test is reliable and reproducible.
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Table 3. Sensitivity, specificity, PPV and NPV of the Xpert MTB/
RIF® test
N=103 General
(CI)
Positive Ziehl 
Neelsen (CI)
Negative Ziehl 
Neelsen (CI)
Sensitivity %
Specificity % 
PPV
NPV
91 (0.73-0.97)
92 (0.81-0.96)
83 (0.65-0.92)
96 (0.86-0.98)
  94 (0.69-0.99)
100 (0.05-0.89)
100 (0.75-0.99)
  50 (0.02-0.97)
87 (0.58-0.97)
91 (0.81-0.96)
68 (0.43-0.86)
97 (0.88-0.99)
PPV: Positive predictive value, NPV: Negative predictive value
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